141 related articles for article (PubMed ID: 27941318)
21. Treatment of basal cell carcinoma with curettage alone.
Barlow JO; Zalla MJ; Kyle A; DiCaudo DJ; Lim KK; Yiannias JA
J Am Acad Dermatol; 2006 Jun; 54(6):1039-45. PubMed ID: 16713459
[TBL] [Abstract][Full Text] [Related]
22. [Basal cell carcinoma of the nose].
Bonvallot T; Raulo Y; Zeller J; Faivre JM; Horn G; Baruch J
Ann Dermatol Venereol; 1993; 120(3):209-14. PubMed ID: 8239358
[TBL] [Abstract][Full Text] [Related]
23. The appropriateness of curettage and electrodesiccation for the treatment of basal cell carcinomas.
Alexiades-Armenakas M; Ramsay D; Kopf AW
Arch Dermatol; 2000 Jun; 136(6):800. PubMed ID: 10871955
[No Abstract] [Full Text] [Related]
24. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
25. Incompletely excised basal cell carcinoma: residual tumor rates at Mohs re-excision.
Palmer VM; Wilson PR
Dermatol Surg; 2013 May; 39(5):706-18. PubMed ID: 23294110
[TBL] [Abstract][Full Text] [Related]
26. Adjunct use of optical coherence tomography increases the detection of recurrent basal cell carcinoma over clinical and dermoscopic examination alone.
Hussain AA; Themstrup L; Nürnberg BM; Jemec G
Photodiagnosis Photodyn Ther; 2016 Jun; 14():178-84. PubMed ID: 27109055
[TBL] [Abstract][Full Text] [Related]
27. Status of curettage and desiccation in the treatment of primary basal cell carcinoma.
Salasche SJ
J Am Acad Dermatol; 1984 Feb; 10(2 Pt 1):285-7. PubMed ID: 6715597
[No Abstract] [Full Text] [Related]
28. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report.
Rigel DS; Torres AM; Ely H
J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s15-6. PubMed ID: 18277458
[TBL] [Abstract][Full Text] [Related]
29. Favourable results of Mohs micrographic surgery for basal cell carcinoma.
Gniadecki R; Glud M; Mortensen K; Bang B; Biskup E; Omland SH
Dan Med J; 2015 Dec; 62(12):A5171. PubMed ID: 26621396
[TBL] [Abstract][Full Text] [Related]
30. Defining recurrence of nonmelanoma skin cancer after Mohs micrographic surgery: Report of the American College of Mohs Surgery Registry and Outcomes Committee.
Leitenberger JJ; Rogers H; Chapman JC; Maher IA; Fox MC; Harmon CB; Bailey EC; Odland P; Wysong A; Johnson T; Wisco OJ
J Am Acad Dermatol; 2016 Nov; 75(5):1022-1031. PubMed ID: 27546292
[TBL] [Abstract][Full Text] [Related]
31. Therapy for basal cell epitheliomas by curettage only. Further study.
McDaniel WE
Arch Dermatol; 1983 Nov; 119(11):901-3. PubMed ID: 6639109
[TBL] [Abstract][Full Text] [Related]
32. Incompletely excised basal cell carcinoma: a management dilemma?
Sussman LA; Liggins DF
Aust N Z J Surg; 1996 May; 66(5):276-8. PubMed ID: 8634041
[TBL] [Abstract][Full Text] [Related]
33. Five year basal cell carcinoma recurrence rates treated with curettage and cautery, a single centre retrospective cohort study.
Barea A; Martinucci M; Wertheim D; Morley IFI; Thomson D; Soldin MG
J Plast Reconstr Aesthet Surg; 2021 Aug; 74(8):1931-1971. PubMed ID: 34134938
[No Abstract] [Full Text] [Related]
34. A video-based educational pilot for basal cell carcinoma (BCC) treatment: A randomized controlled trial.
Love EM; Manalo IF; Chen SC; Chen KH; Stoff BK
J Am Acad Dermatol; 2016 Mar; 74(3):477-83.e7. PubMed ID: 26777101
[TBL] [Abstract][Full Text] [Related]
35. Failure of curettage and electrodesiccation for removal of basal cell carcinoma.
Suhge d'Aubermont PC; Bennett RG
Arch Dermatol; 1984 Nov; 120(11):1456-60. PubMed ID: 6497413
[TBL] [Abstract][Full Text] [Related]
36. Curettage vs. cryosurgery for superficial basal cell carcinoma: a prospective, randomised and controlled trial.
Backman EJ; Polesie S; Berglund S; Gillstedt M; Sjöholm A; Modin M; Paoli J
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1758-1765. PubMed ID: 35543079
[TBL] [Abstract][Full Text] [Related]
37. Axillary basal cell carcinoma: case report and literature review.
Lin CT; Chen SG; Chen TM; Chang SC
Acta Dermatovenerol Croat; 2011; 19(2):107-9. PubMed ID: 21703158
[TBL] [Abstract][Full Text] [Related]
38. Role of cyclooxygenase-2, ezrin and matrix metalloproteinase-9 as predictive markers for recurrence of basal cell carcinoma.
El-Khalawany MA; Abou-Bakr AA
J Cancer Res Ther; 2013; 9(4):613-7. PubMed ID: 24518705
[TBL] [Abstract][Full Text] [Related]
39. Clinical and pathologic parameters predicting recurrence of facial basal cell carcinoma: a retrospective audit in an advanced care center.
Troeltzsch M; Probst FA; Knösel T; Mast G; Ehrenfeld M; Otto S
Int J Dermatol; 2016 Nov; 55(11):1281-1288. PubMed ID: 27420481
[TBL] [Abstract][Full Text] [Related]
40. Cryosurgery in difficult to treat basal cell carcinoma.
Jaramillo-Ayerbe F
Int J Dermatol; 2000 Mar; 39(3):223-9. PubMed ID: 10759968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
